相关实验视频

Updated: Jun 7, 2025

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

开发新的抗癌药物:设计,合成,生物评估和几种功能化胺-5-碳二烯的in silico研究作为针对乳腺癌的小分子调节器

Waleed A Badawi¹, Tarek M Okda², Shrouk M Abd El Wahab¹

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Damanhour, 22511, Egypt.

Bioorganic chemistry

|November 18, 2024

概括

新的pyrimidine-carbonitrile化合物显示出强大的抗乳腺癌活性. 这些新型候选药物有效地向激素依赖和独立的乳腺癌细胞,提供有前途的治疗潜力.

科学领域:

药用化学医学化学
在瘤学瘤学.
药物发现药物发现药物发现

背景情况:

乳腺癌仍然是全球女性死亡的主要原因.
新型,强效和选择性抗乳腺癌药物的开发至关重要.
现有疗法面临诸如耐药性和副作用等挑战.

研究的目的:

设计和合成新型的4-氨酸胺-5-碳烯衍生物.
评估这些化合物对人类乳腺癌细胞系的抗增殖和细胞毒性活动.
调查有前途的候选者的作用机制和结.

主要方法:

合成和结构优化皮里米丁 - 碳烯衍生物.
针对MCF-7和MDA-MB-231乳腺癌细胞系的体外抗增殖试验.
酶抑制试验 (ARO,EGFR),基于细胞的试验 (CDK,HSP90,PI3K),细胞周期分析,亡诱导和分子对接.

主要成果:

几种化合物对激素依赖性 (MCF-7) 和独立性 (MDA-MB-231) 乳腺癌细胞表现出显著的细胞毒性活性.
化合物3c和6a显示出强烈的芳香酶 (ARO) 抑制,而4c和4d则抑制了表皮生长因子受体 (EGFR).
活性化合物在正常细胞中表现出良好的安全性,诱导了亡,并显示出有前途的结相互作用.

结论:

设计的4-hydrazinylpyrimidine-5-carbonitrile衍生物代表了一类有前途的抗乳腺癌药物.
化合物3c,4c,4d和6a被确定为进一步优化的主要候选物.
这些发现支持了这些化合物在乳腺癌治疗中的未来治疗应用的潜力.

关键词:

乳腺癌是什么? 乳腺癌是什么?酶抑制可以抑制酶.在 silico 接研究.皮里米丁 - 摩尔福林结合物皮里米丁-皮皮里丁结合物

更多相关视频

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...